Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 6/20 | 0.52 |
| ▸ | RXRA | P19793 | 5/20 | 0.52 |
| ▸ | RXRG | P48443 | 4/20 | 0.52 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.46 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392988 | 0.83 | RXRB (0.43) | RXRBRXRARXRGBCL2A1MRGPRX4 | |
| SCHEMBL11215834 | 0.79 | RXRB (0.50) | RXRBRXRARXRGMRGPRX4 | |
| SCHEMBL21392984 | 0.77 | ALDH1A1 (0.42) | RXRBRXRARXRG | |
| SCHEMBL20456630 | 0.76 | RXRA (0.49) | RXRBRXRARXRG | |
| SCHEMBL31565004 | 0.76 | RXRA (0.49) | RXRBRXRARXRG | |
| SCHEMBL2428985 | 0.75 | BCL2A1 (0.50) | BCL2A1GSTO1TRPM8 | |
| SCHEMBL31335509 | 0.72 | TRAP1 (0.46) | — | |
| SCHEMBL4622662 | 0.72 | RXRB (0.40) | RXRBRXRARXRGMRGPRX4 | |
| SCHEMBL27847921 | 0.72 | TRPM8 (0.64) | BCL2A1GSTO1TRPM8 | |
| SCHEMBL31335612 | 0.71 | HSP90AA1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| US-12161648-B2 | Covalent targeting of E3 ligases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3863642-A1 | COVALENT TARGETING OF E3 LIGASES | The Regents of the University of California (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113164495-A | Covalent targeting of E3 ligase | 加利福尼亚大学董事会 | 2021-07-23 | — | — | CN | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161648-B2 | Covalent targeting of E3 ligases | RNF114, RNF4, RNF168 | RXRB 2973/4885RXRA 2823/4885RXRG 2484/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | RXRB 1975/4885RXRA 2028/4885RXRG 1851/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | RXRB 2973/4885RXRA 2823/4885RXRG 2484/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | RXRB 3292/4885RXRA 3146/4885RXRG 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.